Cargando…
Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy
BACKGROUND: High risk of recurrence/progression bladder tumours is treated with Bacillus Calmette-Guérin (BCG) immunotherapy after complete resection of the tumour. Approximately 75% of these tumours express the uncommon carbohydrate antigen sialyl-Tn (Tn), a surrogate biomarker of tumour aggressive...
Autores principales: | Lima, L, Severino, P F, Silva, M, Miranda, A, Tavares, A, Pereira, S, Fernandes, E, Cruz, R, Amaro, T, Reis, C A, Dall'Olio, F, Amado, F, Videira, P A, Santos, L, Ferreira, J A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798967/ https://www.ncbi.nlm.nih.gov/pubmed/24064971 http://dx.doi.org/10.1038/bjc.2013.571 |
Ejemplares similares
-
Expression of sialyl-Tn sugar antigen in bladder cancer cells affects response to Bacillus Calmette Guérin (BCG) and to oxidative damage
por: Severino, Paulo F., et al.
Publicado: (2017) -
Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis x in Gastrointestinal Cancers
por: Trinchera, Marco, et al.
Publicado: (2017) -
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens
por: Loureiro, Liliana R., et al.
Publicado: (2015) -
Sialyl-Tn in Cancer: (How) Did We Miss the Target?
por: Julien, Sylvain, et al.
Publicado: (2012) -
The Role of Sialyl-Tn in Cancer
por: Munkley, Jennifer
Publicado: (2016)